Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.79 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153726 | 0.91 | AVPR1A (0.74) | AVPR1AAVPR2 | |
| SCHEMBL3554976 | 0.88 | AVPR1A (1.00) | AVPR1AAVPR2 | |
| SCHEMBL4145382 | 0.88 | AVPR2 (0.63) | AVPR1AAVPR2 | |
| SCHEMBL3538425 | 0.86 | AVPR1A (0.76) | AVPR1AAVPR2 | |
| SCHEMBL7332271 | 0.85 | AVPR1A (0.72) | AVPR1AAVPR2 | |
| SCHEMBL7313070 | 0.84 | AVPR1A (1.00) | AVPR1AAVPR2 | |
| SCHEMBL7316385 | 0.84 | AVPR1A (0.71) | AVPR1AAVPR2 | |
| SCHEMBL6624843 | 0.83 | AVPR1A (0.77) | AVPR1AAVPR2 | |
| SCHEMBL13403212 | 0.83 | AVPR1A (0.85) | AVPR1AAVPR2 | |
| SCHEMBL5741818 | 0.83 | AVPR1A (0.70) | AVPR1AAVPR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | claimed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | claimed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | claimed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | claimed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | claimed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7465722-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7223752-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060276456-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | AVPR2, AVPR1B, SSTR3 | AVPR1A 4/4885AVPR2 1/4885RAB9A 1125/4885 |
| US-20060276456-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | AVPR1A 4/4885AVPR2 1/4885RAB9A 1125/4885 |
| US-20030018024-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR2 1/4885RAB9A 3092/4885 |
| US-20050075328-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | AVPR1A 4/4885AVPR2 1/4885RAB9A 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.